Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A comparative study of five technologically diverse CFTR testing platforms.

Monique A Johnson1, Marvin J Yoshitomi, C Sue Richards

  • 1Department of Molecular and Medical Genetics, Molecular Diagnostic Center, Oregon Health and Science University, Portland, OR, USA.

The Journal of Molecular Diagnostics : JMD
|June 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).

Genetics in medicine : official journal of the American College of Medical Genetics·2025
Same author

Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG).

Genetics in medicine : official journal of the American College of Medical Genetics·2024
Same author

Novel recruitment approaches and operational results for a statewide population Cohort for cancer research: The Healthy Oregon Project.

Journal of clinical and translational science·2024
Same author

Population screening shows risk of inherited cancer and familial hypercholesterolemia in Oregon.

American journal of human genetics·2023
Same author

ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).

Genetics in medicine : official journal of the American College of Medical Genetics·2023
Same author

Missense variant in RBM10 associated with mild and non-lethal form of TARP syndrome.

Clinical genetics·2023
Same journal

Epigenetic CD4+ T-Cell Quantification from Dried Blood Spots Using a qPCR-Based Assay.

The Journal of molecular diagnostics : JMD·2026
Same journal

Segmental Copy Number Variant Detection Using an Amplicon-based NGS Panel for Integrated Glioma Classification.

The Journal of molecular diagnostics : JMD·2026
Same journal

Clinical Validation of the Roche cobas and cobas 4800 Human Papillomavirus Tests on Self-Collected Vaginal Dry Swabs versus Practitioner-Collected Cervical Specimens Using the VALHUDES Protocol.

The Journal of molecular diagnostics : JMD·2026
Same journal

Long-Read Nanopore Sequencing Enhances BRCA1/2 Variant Detection Compared with Ion Torrent Analysis.

The Journal of molecular diagnostics : JMD·2026
Same journal

Endonuclease-Assisted Selective Exponential Amplification for Ultrasensitive Enrichment and Detection of Low-Abundance Mutant Alleles in Lung Cancer.

The Journal of molecular diagnostics : JMD·2026
Same journal

Validation of NTRK Fusion Detection Using an Ultrarapid, Fully Automated Cartridge-Based PCR Assay.

The Journal of molecular diagnostics : JMD·2026
See all related articles

Choosing a cystic fibrosis (CF) testing platform requires evaluating multiple factors. Five diverse CF testing platforms demonstrated comparable performance in sensitivity, specificity, and no-call rates for mutation detection.

Area of Science:

  • Clinical Diagnostics
  • Molecular Biology
  • Genetic Testing

Background:

  • Numerous cystic fibrosis (CF) testing platforms utilizing diverse technologies are available for clinical laboratories.
  • Selection criteria for CF platforms encompass sensitivity, specificity, genotyping capabilities, workflow integration, and cost-effectiveness.

Purpose of the Study:

  • To evaluate and compare the performance of five distinct cystic fibrosis testing platforms.
  • To provide data to aid clinical laboratories in selecting the most appropriate CF testing platform based on specific needs.

Main Methods:

  • Five technologically diverse CF testing platforms were evaluated: eSensor, InPlex, oligonucleotide ligation assay, Signature liquid bead array, and Tag-It liquid bead array.
  • A core set of 150 samples, focusing on ACMG/ACOG recommended mutations, were tested across multiple runs for each platform.

Related Experiment Videos

  • Performance metrics including sensitivity, specificity, and no-call rates were assessed.

    • Main Results:

    • All five evaluated cystic fibrosis testing platforms demonstrated comparable performance regarding sensitivity, specificity, and no-call rates.
    • The study highlights the importance of considering various parameters beyond core performance metrics when selecting a platform.

    Conclusions:

    • The evaluated cystic fibrosis testing platforms offer comparable diagnostic accuracy for common CF mutations.
    • Laboratory-specific factors, including workflow, instrumentation, and desired flexibility, should guide the final platform selection process.